Login
$SER
$1.42 +$0.00 (0.0%) After hours

$SER 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

– Independent Safety Monitoring Committee recommended advancement of SER-252 in Parkinson's disease to Cohort 2

09 Oct 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

State of Delaware Secretary of State Division of Corporations Delh•ered 12 :22 P:\1 10/05/2026 FILED 12:22 PM 10/05/2026 SR 20264597278 - File Number 6241730 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK OF SERINA TH...

09 Sep 2026 8-K: Other Events

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

27 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

On August 21, 2026, Serina Therapeutics, Inc. (the “Company”) entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) and a related Registration Rights Agreement (the “Registration Rights Agreement”), each dated as of A...

13 Aug 2026 8-K: Results of Operations and Financial Condition

–Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 -

23 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Amended and Restated Employment Agreement (this “Agreement”) is made and entered into effective as of the 19th day of July, 2026 (the “Restatement Date”), by and between (i) Serina Therapeutics, Inc., a Delaware corporation (“Serina...

22 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

HUNTSVILLE, Ala., July 22, 2026, (GLOBE NEWSWIRE) – Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform™ drug optimization technology, ...

24 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

THIS AMENDMENT TO THE SERINA THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN (this “Amendment”) is effective as of June 17, 2026. Capitalized terms used and not defined herein shall have the meanings ascribed to them in the Plan (as define...

14 May 2026 8-K: Results of Operations and Financial Condition

–Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson’s Disease; TFL data from the SAD study arm targeted for first half of 2027 -

21 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year

Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent.

25 Mar 2026 8-K: Results of Operations and Financial Condition

HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today...

23 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +3 more

This Securities Purchase Agreement (together with all exhibits and schedules hereto, this “Agreement”) is entered into as of March 17, 2026, by and between Serina Therapeutics, Inc., a Delaware corporation (the “Company”), Greg Bailey (t...

28 Jan 2026 8-K: Other Events

Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease

15 Jan 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Regulation FD Disclosure

– HUNTSVILLE, Jan 15, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for...

10 Dec 2025 8-K: Other Events

– Company addresses FDA requests regarding formulation excipient

13 Nov 2025 8-K: Results of Operations and Financial Condition

HUNTSVILLE, November 13, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, f...

12 Nov 2025 8-K: Submission of Matters to a Vote of Security Holders

The Board of Directors of Serina Therapeutics, Inc. (the “Company”) held the Company’s 2025 Annual Meeting of the Stockholders (the “Annual Meeting”) on November 7, 2025. A quorum was present at the meeting. The final results of voting f...

03 Nov 2025 8-K: Other Events

- FDA requests additional information on a formulation component -

06 Oct 2025 8-K: Other Events

Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease

15 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support